Education
About Us
Working with TipRanks
Follow Us
Relmada Therapeutics Inc (RLMD)
:RLMD
Total Valuation
Relmada Therapeutics has a market cap or net worth of $9.49M. The enterprise value is -$29.22M.
Market Cap$9.49M
Enterprise Value-$29.22M
Share Statistics
Relmada Therapeutics has 33.19M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding33.19M
Owened by Insiders2.40%
Owened by Instutions6.01%
Financial Efficiency
Relmada Therapeutics’s return on equity (ROE) is 0.00 and return on invested capital (ROIC) is ―.
Return on Equity (ROE)0.00%
Return on Assets (ROA)0.00%
Return on Invested Capital (ROIC)―
Return on Capital Employed (ROCE)0.00%
Revenue Per Employee$0
Profits Per Employee-$5,087,492.706
Employee Count17
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Relmada Therapeutics is 0.00. Relmada Therapeutics’s PEG ratio is 0.00.
PE Ratio0.00
PS Ratio0.00
PB Ratio0.44
Price to Fair Value0.44
Price to FCF0.00
Price to Operating Cash Flow0.00
PEG Ratio0.00
Income Statement
In the last 12 months, Relmada Therapeutics had revenue of $0.00 and earned -$86.49M in profits. Earnings per share was -$2.87.
Revenue$0.00
Gross Profit$0.00
Operating Income-$91.64M
Pretax Income-$86.49M
Net Income-$86.49M
EBITDA-41.83M
Earnings Per Share (EPS)-2.87
Cash Flow
In the last 12 months, operating cash flow was -$53.21M and capital expenditures $0.00, giving a free cash flow of -$53.21M billion.
Operating Cash Flow-$53.21M
Free Cash Flow-$53.21M
Free Cash Flow per Share-$1.60
Dividends & Yields
Relmada Therapeutics pays an annual dividend of , resulting in a dividend yield of
Dividend Per Share
Dividend Yield
Payout Ratio
Free Cash Flow Yield0.00%
Earnings Yield0.00%
Stock Price Statistics
Beta1.46
52-Week Price Change-93.26%
50-Day Moving Average0.29
200-Day Moving Average1.97
Relative Strength Index (RSI)36.82
Average Volume (3m)385.45K
Important Dates
Relmada Therapeutics upcoming earnings date is May 7, 2025, After Close.
Last Earnings DateMar 27, 2025
Next Earnings DateMay 7, 2025
Ex-Dividend Date―
Financial Position
Relmada Therapeutics as a current ratio of 4.45, with Debt / Equity ratio of 0.00
Current Ratio4.45
Quick Ratio4.45
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Relmada Therapeutics has paid -$41.83M in taxes.
Income Tax-$41.83M
Effective Tax Rate0.00%
Enterprise Valuation
Relmada Therapeutics EV to EBITDA ratio is 0.00, with an EV/FCF ratio of 0.00.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow0.00
EV to Operating Cash Flow0.00
Balance Sheet
Relmada Therapeutics has $54.12M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$54.12M billion.
Cash & Marketable Securities$54.12M
Total Debt$0.00
Net Cash-$54.12M
Net Cash Per Share-$1.63
Tangible Book Value Per Share$1.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Relmada Therapeutics is $1.00, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$1.00
Price Target Upside233.33%
Analyst ConsensusHold
Analyst Count2
Revenue Growth Forecast
EPS Growth Forecast19.21%